How Are Platelet-Derived Extracellular Vesicles Isolated and Characterized?

Platelet-derived extracellular vesicles (pEVs) are membrane-bound particles released by platelets constitutively and in response to activation.

Studying these vesicles requires more than simply detecting nanoscale particles.

A scientifically robust extracellular-vesicle workflow typically involves several stages:

Platelet Source → Pre-Analytical Control → Platelet Activation → EV Release → Separation → Particle Analysis → Morphological Analysis → Molecular Characterization → Cellular-Origin Verification → Purity Assessment

Methods such as Nanoparticle Tracking Analysis (NTA) can estimate particle concentration and size distribution, while Transmission Electron Microscopy (TEM) provides morphological information.

Protein-based analyses can investigate EV-associated proteins, while platelet-associated markers such as CD41, CD42b and CD61 can help support platelet origin.

However, no single analytical technique is sufficient to establish the complete identity, origin and purity of an extracellular-vesicle preparation.

Current international guidance therefore emphasizes multimodal characterization and transparent reporting rather than relying on particle count or a single EV marker.

1. What Are Platelet-Derived Extracellular Vesicles?

Platelets are small anucleate blood components best known for their role in hemostasis.

However, platelet biology extends far beyond clot formation.

Platelets participate in processes including:

• inflammation,

• immune signaling,

• angiogenesis,

• tissue repair,

• intercellular communication,

• and vascular biology.

One mechanism through which platelets participate in these processes is the release of extracellular vesicles (EVs).

These membrane-bound particles can contain complex biological cargo including:

• proteins,

• lipids,

• nucleic acids,

• enzymes,

• signaling molecules,

• and membrane-associated proteins.

Platelet-derived EV populations are heterogeneous, and their biological composition can change depending on the conditions under which platelets release them.

2. Why Is Platelet EV Characterization Difficult?

Extracellular vesicles do not exist in biological samples in isolation.

Plasma and platelet-derived preparations may also contain:

• soluble plasma proteins,

• lipoproteins,

• protein aggregates,

• platelet fragments,

• intact or residual platelets,

• cellular debris,

• membrane fragments,

• and other extracellular particles.

Some of these components overlap with EVs in physical properties such as size or density.

This creates one of the fundamental problems of extracellular-vesicle science:

Detecting a nanoscale particle does not automatically establish that the particle is an extracellular vesicle.

A 2025 study illustrates the issue particularly well: separating platelet EVs from lipoproteins remains challenging because lipoproteins can possess biophysical characteristics similar to EVs.

This is why EV characterization requires multiple complementary analytical approaches.

3. The Process Begins Before EV Isolation

One of the most overlooked aspects of EV analysis is the pre-analytical stage.

Before asking how EVs are isolated, researchers must ask:

Where did the sample come from?

and:

How was it handled?

Relevant variables can include:

• blood collection method,

• anticoagulant,

• processing time,

• temperature,

• centrifugation conditions,

• platelet concentration,

• leukocyte contamination,

• storage conditions,

• freeze-thaw cycles,

• and platelet activation during handling.

This is especially important for platelet-derived EV research because platelets can release vesicles during sample preparation itself.

Poor sample handling can therefore alter the EV population before the intended experiment even begins.

4. Platelet Activation and EV Release

Platelets can release extracellular vesicles constitutively, but activation can substantially increase vesiculation.

Importantly, different activation pathways may not produce identical EV populations.

Aatonen and colleagues compared several platelet activation conditions and demonstrated that activation affected both:

EV quantity

and

EV protein composition.

The main EV population detected in their experimental system was approximately 100–250 nm, with more than 90% below 500 nm. Different activation stimuli generated heterogeneous EV populations with different molecular cargo.

This leads to an important principle:

The activation method is part of EV characterization.

It should not be treated simply as an upstream procedural detail.

5. How Are Platelet-Derived EVs Separated?

There is no single universally optimal EV isolation method.

The appropriate method depends on:

• starting material,

• desired EV population,

• downstream analysis,

• required purity,

• required recovery,

• sample volume,

• and intended application.

Common approaches include the following.

Differential Centrifugation

Differential centrifugation separates components through sequential centrifugation steps using different centrifugal forces.

Larger cells and debris are generally removed first, followed by smaller components.

Historically, this has been one of the most widely used approaches in EV research.

However, recovery and purity can vary, and some EV populations can be lost during the process.

Aatonen et al. specifically noted that differential centrifugation may lose larger vesicle populations and that separation of platelet remnants is particularly important in platelet EV research.

6. Ultracentrifugation

Ultracentrifugation uses very high centrifugal forces to sediment small extracellular particles.

It has historically been used extensively in EV research.

However, the method has limitations.

Depending on the protocol, ultracentrifugation can potentially:

• co-isolate non-EV components,

• generate aggregates,

• affect recovery,

• introduce variability,

• and require specialized laboratory equipment.

Therefore, ultracentrifugation should not automatically be interpreted as synonymous with “pure exosome isolation.”

The isolation method itself does not establish vesicle identity.

7. Size-Exclusion Chromatography

Size-Exclusion Chromatography (SEC) separates components primarily according to hydrodynamic size.

SEC can be useful when researchers want to separate EV-containing fractions from a substantial proportion of soluble proteins.

For example, Nyam-Erdene and colleagues characterized platelet EVs from human platelet lysates and used size-exclusion chromatography to separate EVs from proteins.

They reported approximately 73–85% EV recovery in their experimental system while maintaining particle size, negative zeta potential and expression of platelet-associated CD41 and CD61.

This illustrates an important point:

EV separation should be evaluated not only by purity, but also by recovery.

A method that produces very clean material but loses most EVs may not be appropriate for every application.

8. Filtration and Other Separation Approaches

Depending on the application, EV workflows may also use:

• membrane filtration,

• ultrafiltration,

• affinity-based capture,

• precipitation,

• density-gradient methods,

• chromatographic separation,

• or combinations of several techniques.

Each method introduces different trade-offs involving:

Yield ↔ Purity ↔ Recovery ↔ Scalability ↔ Reproducibility

Consequently, the question should not simply be:

“What is the best EV isolation method?”

A better scientific question is:

“Which separation strategy is appropriate for the intended EV population and downstream analysis?”

9. Separation Is Not the Same as Characterization

This distinction is fundamental.

After a biological preparation has undergone an EV separation procedure, researchers still need to determine:

• how many particles are present,

• what size they are,

• whether vesicular structures are present,

• what proteins they carry,

• where they originated,

• what contaminants remain,

• and potentially whether they exhibit biological activity.

Therefore:

EV separation ≠ EV characterization

and:

EV enrichment ≠ purified exosome identification

This distinction is central to MISEV2023.

10. Nanoparticle Tracking Analysis — NTA

NTA is one of the most frequently used techniques in EV research.

The method tracks the Brownian movement of individual particles suspended in liquid and uses this information to estimate particle size and concentration.

NTA can therefore provide useful information about:

Particle Concentration

For example:

particles/mL

Particle Size Distribution

For example, whether the preparation contains a dominant population within a particular nanoscale range.

Aatonen et al. used NTA together with electron microscopy to characterize platelet-derived EV populations.

But there is an extremely important limitation.

What NTA does NOT establish

NTA alone does not tell us that:

• every particle is an EV,

• every EV is platelet-derived,

• every particle is an exosome,

• or every particle is biologically active.

Therefore:

Particle count ≠ exosome count

This is particularly important when particle measurements are used in commercial or clinical communication.

11. Transmission Electron Microscopy — TEM

Transmission Electron Microscopy provides structural and morphological information at very high resolution.

TEM can help researchers visualize structures consistent with extracellular vesicles and assess:

• morphology,

• approximate size,

• membrane structures,

• and preparation heterogeneity.

In PRP-derived exosome research, TEM has been used alongside biochemical characterization to investigate vesicle morphology following platelet activation.

However, TEM also has limitations.

Sample preparation can affect morphology and apparent particle size.

For example, Aatonen et al. observed differences between particle sizes measured by NTA and TEM and discussed sample-preparation-related shrinkage as one potential explanation.

Thus:

NTA and TEM provide complementary information.

Neither replaces the other.

12. EV-Associated Protein Markers

Molecular characterization is another important layer.

Proteins commonly investigated in EV research include tetraspanins such as:

• CD9

• CD63

• CD81

and other EV-associated proteins such as:

• TSG101

• ALIX

depending on the biological system and EV population being investigated.

However, detecting one such marker should not automatically lead to the conclusion:

“These particles are purified exosomes.”

Modern EV characterization relies on multiple lines of evidence.

MISEV2023 specifically emphasizes the need for appropriate characterization and transparent reporting of EV-associated and non-EV components.

13. How Do We Establish Platelet Origin?

For platelet-derived EVs, demonstrating vesicular characteristics is only part of the problem.

Researchers also need evidence supporting platelet origin.

Platelet-associated surface proteins can be investigated for this purpose.

Important examples include:

CD41

Integrin αIIb.

CD61

Integrin β3.

Together, CD41/CD61 form the platelet integrin αIIbβ3 complex.

CD42b

Glycoprotein Ib alpha, another platelet-associated membrane protein.

Detection of platelet-associated markers can help support the conclusion that an EV population originated from platelets.

For example, platelet EVs isolated from human platelet lysates have been shown to express CD41 and CD61.

14. Why One Marker Is Not Enough

Consider a hypothetical sample.

NTA shows:

50 billion particles/mL

Western blot shows:

CD63 positive

Can we conclude that the sample contains:

50 billion platelet-derived exosomes/mL?

No.

We still do not know whether:

• all particles measured by NTA are EVs,

• all EVs express CD63,

• the particles originate from platelets,

• non-vesicular particles are present,

• or the population consists specifically of exosomes.

A more convincing characterization strategy would combine several dimensions:

Particle Analysis + Morphology + EV-Associated Markers + Platelet-Origin Markers + Contaminant Assessment

This is the fundamental logic behind multimodal EV characterization.

15. Purity: The Often-Ignored Variable

A preparation can contain a high number of particles while still containing substantial quantities of non-EV material.

Potential contaminants include:

• albumin,

• immunoglobulins,

• lipoproteins,

• protein aggregates,

• cellular fragments,

• and residual platelets.

This means that simply maximizing particle concentration is not necessarily equivalent to maximizing EV purity.

Recent work on platelet EV isolation continues to identify separation from lipoproteins as an important technical challenge.

The scientific goal should therefore not be:

maximum particles

alone.

It should be:

well-characterized particles with known origin, composition and preparation methodology.

16. EV Recovery vs. EV Purity

There is another important trade-off.

Imagine two separation methods.

Method A

Recovers 90% of the EV population but also retains substantial soluble protein.

Method B

Produces a much cleaner fraction but recovers only 20% of the original EVs.

Which method is better?

There is no universal answer.

It depends on the intended application.

This is why important performance variables include:

• particle recovery,

• purity,

• concentration,

• size distribution,

• biological activity,

• reproducibility,

• and scalability.

The platelet lysate SEC study illustrates this concept by reporting EV recovery alongside characterization rather than reporting particle concentration alone.

17. Why “Exosome Isolation” Can Be a Problematic Term

The word exosome describes an EV subclass associated with a specific endosomal biogenesis pathway.

But many isolation techniques separate particles based primarily on:

• size,

• density,

• affinity,

• or other physical characteristics.

These techniques do not necessarily establish the intracellular origin of every recovered vesicle.

For this reason, MISEV2023 recommends EV terminology based on demonstrable characteristics when precise biogenesis has not been established.

Therefore, terms such as:

small extracellular vesicles

or

platelet-derived extracellular vesicles

may sometimes be scientifically more appropriate than automatically describing an entire preparation as purified exosomes.

18. What Does MISEV2023 Recommend?

MISEV2023 is currently one of the most important international frameworks for EV research.

It addresses:

• nomenclature,

• EV sources,

• pre-analytical variables,

• separation,

• concentration,

• characterization,

• functional studies,

• reporting,

• release and uptake,

• and other experimental considerations.

The document was developed with input from more than 1,000 researchers, reflecting the breadth of the international EV community.

The central philosophy is particularly relevant:

An EV preparation should be described according to what has actually been demonstrated experimentally.

This is a powerful principle for both academic research and commercial technology development.

19. A Practical Characterization Framework for Platelet EVs

For platelet-derived EV research, we can summarize a robust analytical strategy as follows.

Level 1 — Source

Define:

• blood source,

• platelet preparation,

• anticoagulant,

• platelet concentration,

• activation conditions.

Level 2 — Separation

Document:

• centrifugation,

• filtration,

• chromatography,

• precipitation,

• or other methods.

Level 3 — Particle Analysis

Measure:

• concentration,

• size distribution.

Possible technique:

NTA

Level 4 — Morphology

Investigate vesicular structures.

Possible technique:

TEM

Level 5 — EV-Associated Proteins

Investigate appropriate markers such as:

CD9 / CD63 / CD81 / TSG101 / ALIX

depending on the experimental system.

Level 6 — Platelet Origin

Investigate platelet-associated markers such as:

CD41 / CD42b / CD61

Level 7 — Purity

Assess relevant non-EV components and contaminants.

Level 8 — Function

Where appropriate, investigate biological activity using suitable validated assays.

This produces a much stronger scientific picture than particle count alone.

20. What Would an Ideal Platelet EV Report Look Like?

Instead of reporting:

“47.5 billion exosomes/mL”

a scientifically stronger report could describe:

Particle concentration:X particles/mL

Particle-size distribution:X–Y nm

Morphology:TEM-compatible vesicular structures observed

EV-associated markers:CD9 / CD63 / CD81 etc.

Platelet-associated markers:CD41 / CD61 / CD42b

Purity assessment:Relevant non-EV components evaluated

Preparation protocol:Defined platelet concentration, activation conditions and separation workflow

This allows researchers and clinicians to understand what was actually measured.

21. Why This Matters for Regenerative Medicine

The future of EV-based regenerative technologies depends on reproducibility.

If two preparations are both called:

“platelet-derived exosomes”

but differ substantially in:

• platelet source,

• activation,

• separation,

• concentration,

• size,

• protein composition,

• purity,

• and biological activity,

they cannot automatically be considered equivalent biological preparations.

This is why characterization becomes part of the technology itself.

The future question will increasingly shift from:

“How many exosomes does the system produce?”

toward:

“What extracellular-vesicle population does the system produce, how was it characterized, and how reproducible is the preparation?”

That is a far more scientifically meaningful question.

22. Implications for Point-of-Care EV Preparation

Laboratory EV isolation and point-of-care biological preparation are not necessarily the same objective.

A laboratory may prioritize extremely high purity for molecular analysis.

A point-of-care system may prioritize:

• closed processing,

• autologous material,

• reproducibility,

• practical processing time,

• biological recovery,

• and standardized workflow.

Therefore, point-of-care EV technologies should not necessarily be judged against laboratory purification protocols alone.

Instead, the final preparation should be described accurately according to:

what is produced, what is retained and what has actually been characterized.

This distinction is especially important as platelet-derived technologies move from experimental research toward translational regenerative medicine.

STR Scientific Perspective

At STR Biotechnologies, we believe that the future of platelet-derived extracellular-vesicle technologies will depend increasingly on characterization and standardization rather than particle count alone.

A scientifically responsible development pathway can be summarized as:

Standardized PRP Preparation↓Controlled Platelet Activation↓Reproducible EV Release↓Controlled Biological Processing↓Particle Characterization↓EV Identity Assessment↓Platelet-Origin Verification↓Purity Assessment↓Biological Evaluation

For technologies such as ExoPrime®, this creates an important future scientific objective:

moving from a platelet-derived particle preparation toward a well-characterized and reproducible platelet-derived extracellular-vesicle preparation platform.

Importantly, the scientific literature cited in this article evaluates platelet EV biology and analytical methodologies generally. It should not be interpreted as direct clinical validation of ExoPrime® unless the STR system itself was evaluated in the cited study.

Conclusion

Platelet-derived extracellular-vesicle research has advanced significantly, but isolation alone is not sufficient to define an EV preparation.

Different separation methods can produce different balances of recovery, purity and particle composition.

Similarly, no single characterization technique can establish EV identity, platelet origin, purity and biological function simultaneously.

A robust strategy therefore combines:

NTA + Morphology + EV-Associated Markers + Platelet-Origin Markers + Purity Assessment

within a clearly documented preparation workflow.

As EV technologies advance toward regenerative-medicine applications, the emphasis should increasingly shift from simply reporting high particle numbers toward identity, origin, purity, reproducibility and biological characterization.

This transition will be fundamental to the scientific maturation of platelet-derived extracellular-vesicle technologies.

1. Related STR Products

ExoPrime® Platelet-Derived Exosome System

ExoPrime® is STR Biotechnologies' autologous platelet-derived biological preparation platform incorporating PRP preparation, controlled platelet processing and secondary processing.

Internal anchor: ExoPrime® Platelet-Derived Exosome System

HighCell® PRP Kit

PRP preparation technology designed for controlled platelet concentration and platelet-rich fraction recovery.

Internal anchor: HighCell® PRP Kit

S&M® PRP Monocap

PRP preparation component incorporated into the ExoPrime workflow.

Internal anchor: S&M® PRP Monocap

LABFUGE®

Centrifugation platform developed for standardized regenerative-medicine preparation protocols.

Internal anchor: LABFUGE® Centrifuge

2. Related Blog Articles

Burada artık yayınladığımız gerçek cluster'ı kullanabiliriz:

Platelet-Derived Extracellular Vesicles in Regenerative Medicine: What Does Current Evidence Show?

Anchor: scientific evidence for platelet-derived extracellular vesicles

ExoPrime® Technology: From PRP to Platelet-Derived Extracellular Vesicle Preparation

Anchor: ExoPrime platelet-derived EV preparation technology

Daha sonra cluster'a ekleyeceğimiz içerikler:

Platelet-Derived Exosomes vs. Extracellular Vesicles: What Is the Difference?

PRP vs. Platelet-Derived Extracellular Vesicles: What Is the Difference?

Why Platelet Activation Matters in Extracellular Vesicle Preparation

Burada yalnızca gerçekten yayınlanmış yazılara link verelim; gelecek başlıkları Related Articles alanında linkmiş gibi göstermeyelim.

3. Scientific References

1. Welsh JA, et al. — MISEV2023: Minimal information for studies of extracellular vesicles.Journal of Extracellular Vesicles. 2024;13:e12404. EV nomenklatürü, separation, characterization ve reporting için temel uluslararası consensus framework. MISEV2023 full text

2. Aatonen MT, et al. — Isolation and characterization of platelet-derived extracellular vesicles.Journal of Extracellular Vesicles. 2014;3:24692. Platelet activation koşullarının EV miktarı ve protein kargosunu değiştirdiğini; NTA, TEM ve proteomics'in birlikte kullanılabileceğini gösteren temel platelet-EV çalışması. Study on PubMed

3. Nyam-Erdene A, et al. — Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates.ACS Biomaterials Science & Engineering. 2021;7:5823–5835. Size-exclusion chromatography, NTA ve platelet markers CD41/CD61 açısından özellikle değerli.

4. Isolation of Platelet-Derived Exosomes from Human Platelet-Rich Plasma: Biochemical and Morphological Characterization.PRP-derived vesicle araştırmasında biochemical characterization ve TEM kullanımını gösteren doğrudan platelet/PRP çalışması.

5. Shedding Light on the Cell Biology of Platelet-Derived Extracellular Vesicles and Their Biomedical Applications.Platelet EV isolation, characterization, biyolojik fonksiyon ve translational applications konularını kapsayan geniş review.

4. FAQ

How are platelet-derived extracellular vesicles isolated?

Platelet EVs can be separated using methods including differential centrifugation, ultracentrifugation, size-exclusion chromatography, filtration, affinity-based approaches and combinations of these methods. The optimal approach depends on the starting material, desired recovery, purity and downstream application.

What is NTA in extracellular-vesicle analysis?

Nanoparticle Tracking Analysis estimates particle concentration and size distribution by analyzing the Brownian movement of particles in suspension. NTA is useful for particle characterization but cannot independently establish that every detected particle is an EV or exosome.

Can NTA determine exosome concentration?

Not by itself. NTA measures particles within its analytical range. Additional evidence is required to characterize vesicular identity, cellular origin and the nature of the EV population.

What markers are used for platelet-derived EVs?

EV studies may investigate proteins such as CD9, CD63 and CD81 together with other appropriate EV-associated proteins. Platelet-associated markers such as CD41, CD42b and CD61 can help support platelet origin. Platelet EVs expressing CD41 and CD61 have been demonstrated experimentally.

Why is TEM used for extracellular vesicles?

Transmission Electron Microscopy provides high-resolution morphological information and can visualize structures consistent with extracellular vesicles. It is generally used as part of a multimodal characterization strategy rather than as a standalone identity test.

Are extracellular vesicles and exosomes the same?

No. Extracellular vesicle is the broader term. “Exosome” refers to an EV subclass associated with a particular biogenesis pathway. MISEV2023 recommends using terminology supported by the available experimental evidence rather than automatically calling all small EVs exosomes.

What is MISEV2023?

MISEV2023 is the International Society for Extracellular Vesicles' current consensus guidance covering EV nomenclature, separation, characterization, functional studies and reporting. It was developed with input from more than 1,000 researchers.

Is a high particle concentration proof of high exosome concentration?

No. Particle concentration alone cannot determine whether all measured particles are EVs, whether they originate from platelets or whether they are specifically exosomes.